Anti-beta-2 glycoprotein I autoantibody (Anti-β2GPI)

Anti-beta-2 glycoprotein I (anti-β2GPI) autoantibodies are pathogenic immunoglobulins that target beta-2 glycoprotein I, a plasma protein with a high affinity for anionic phospholipids [1, 2]. These autoantibodies are a primary diagnostic marker and a key driver of antiphospholipid syndrome (APS), an autoimmune condition characterized by recurrent arterial or venous thrombosis and pregnancy-related complications [1]. The binding of these antibodies to β2GPI, particularly to its Domain I, triggers a conformational change that promotes the activation of endothelial cells, monocytes, and platelets [3, 4]. This interaction leads to the upregulation of pro-thrombotic factors like tissue factor and the activation of the complement cascade, creating a severe hypercoagulable state [3]. Clinically, the presence of these antibodies is associated with a significantly higher risk of clinical events compared to other antiphospholipid antibodies [1]. While current management relies heavily on lifelong anticoagulation to prevent clots, research is increasingly focused on targeted immunotherapies, such as B-cell depletion or complement inhibition, to address the underlying autoimmune pathology [3, 4].

Other names

Anti-beta-2 glycoprotein I antibodiesAnti-B2GPIAnti-apolipoprotein H antibodiesApolipoprotein H antibodiesaB2GPI

Therapeutic strategies include the depletion of B cells to reduce autoantibody production, inhibition of the complement cascade to prevent antibody-mediated tissue injury, and systemic anticoagulation to mitigate the pro-thrombotic state induced by antibody-protein complexes [1, 3].